Lung Cancer Archives

FDA’s ODAC Says Lilly & Innovent Must Run U.S. Trial

Business, Checkpoint Inhibitors, China, Clinical Trial Endpoints, Clinical Trials, Ethnicity, FDA/Regulatory, Lung Cancer, Oncologic Drugs Advisory Committee (ODAC), PD-1 Inhibitors, Primary Endpoints, Progression-Free Survival (PFS), R&D, Therapeutics, United States

The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) recommended that Eli Lilly and Co. and Innovent Biologics Inc. conduct a clinical trial applicable to the U.S. population for the lung cancer drug sintilimab. The U.S. FDA previously raised concerns over a clinical trial conducted entirely in China focused on a single ethnic group.

February 10, 2022/by BioSpace

Roche’s Latest Checkpoint Target Shows Promise for Lung Cancer

Checkpoint Inhibitors, Clinical Trials, Lung Cancer, R&D, Roche

Roche announced promising results for the company’s anti-TIGIT checkpoint inhibitor tiragolumab in PD-L1-positive metastatic non-small cell lung cancer.

December 11, 2021/by BioSpace

Novartis lung cancer drug fails another Phase III trial

Chemotherapy, Clinical Trials, Lung Cancer, Novartis, Primary Endpoints, Progression-Free Survival (PFS), R&D

Novartis said on Oct. 25 the company’s canakinumab drug failed in another clinical trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.

October 25, 2021/by Andrew Humphreys

Merck KGaA, GSK end partnership on former cancer drug hopeful

Bladder Cancer, Breast Cancer, Business, Cervical Cancer, Clinical Data, Clinical Trials, Collaborations, GlaxoSmithKline, Lung Cancer, Partnerships, R&D

Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.

September 30, 2021/by Reuters Health

Merck to buy Acceleron for about $11.5 billion in rare disease drug push

Acquisitions, Blockbusters, Business, Cardiovascular Disease, Clinical Trials, Keytruda, Lung Cancer, Merck, Potential Blockbusters, Pulmonary Arterial Hypertension, R&D, Rare Diseases, Shares

Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.

September 30, 2021/by Reuters Health

Lung Cancer Breakthroughs Touted at ESMO 2021

AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline Data

Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.

September 20, 2021/by Andrew Humphreys

U.S. FDA gives priority review to Roche’s Tecentriq lung cancer drug

Blockbusters, FDA, Lung Cancer, Non-Small Cell Lung Cancer, Priority Review, Therapeutics

The United States Food and Drugs Administration granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Aug. 3.

August 3, 2021/by Andrew Humphreys

Rybrevant Receives U.S. FDA Approval

Approvals, Bispecific Antibody, Companion Diagnostics, EGFR exon 20 insertion mutations, Epidermal Growth Factor Receptor (EGFR), FDA, First-In-Class, Janssen, Johnson & Johnson, Lung Cancer, New Drug Approvals, Non-Small Cell Lung Cancer, Therapeutics

The U.S. Food and Drug Administration granted accelerated approval of Janssen’s Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

May 21, 2021/by Andrew Humphreys

AstraZeneca to withdraw Imfinzi U.S. indication for advanced bladder cancer

Antibodies, AstraZeneca, Bladder Cancer, Blockbusters, FDA, Immunotherapies, Lung Cancer, Voluntary Indication Withdrawal

AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.

February 22, 2021/by Andrew Humphreys

Merck KGaA, GSK suffer lung cancer drug setback

Agreements, Blockbusters, Business, Clinical Trials, Drug Development, GlaxoSmithKline, Immunotherapies, Lung Cancer, R&D, Shares, Therapeutics

Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.

January 20, 2021/by Andrew Humphreys